PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents growing 9.62% while TRVN's declined -28.58%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half of TRVN's -28.58%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of TRVN's -26.21%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.18%
1.25-1.5x TRVN's -4.96%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
Higher Long-Term Investments Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
1.25-1.5x TRVN's -4.46%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half of TRVN's -23.32%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.53%
Less than half of TRVN's 1.04%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Similar yoy changes to TRVN's -100.00%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
100.00%
Less than half of TRVN's -100.00%. David Dodd sees fewer expansions in other current obligations.
-5.06%
1.1-1.25x TRVN's -4.59%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Less than half of TRVN's -5.22%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Less than half of TRVN's -5.12%. David Dodd sees far fewer liability expansions relative to competitor.
3.57%
50-75% of TRVN's 5.88%. Bruce Berkowitz notes minimal new equity relative to competitor.
-2.57%
≥ 1.5x TRVN's -1.31%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
Below half TRVN's -91.38%. Michael Burry sees potential underperformance in building shareholder capital.
8.48%
Below half TRVN's -23.32%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.96%
Higher Total Investments Growth compared to TRVN's zero value, indicating better performance.
-6.20%
Less than half of TRVN's 0.73%. David Dodd sees less overall debt expansion vs. competitor.
-10.07%
Less than half of TRVN's 296.30%. David Dodd sees better deleveraging or stronger cash buildup than competitor.